Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Novartis”

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast CancerRecruiting
NCT04529044Phase 2Updated Jun 5, 2026
Sponsor: OHSU Knight Cancer Institute
Anatomic Stage IV Breast Cancer AJCC v8 · Metastatic Breast Carcinoma · Recurrent Breast Carcinoma
United States
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUSRecruiting
NCT05795140Phase 3Updated Jun 4, 2026
Sponsor: Novartis Pharmaceuticals
Atypical Hemolytic Uremic Syndrome
Brazil, China, Czechia, India, Japan +1 more
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)Recruiting
NCT05660083Phase 2Updated Jun 4, 2026
Sponsor: The Methodist Hospital Research Institute
HER2-negative Breast Cancer · Metastatic Breast Cancer · Metaplastic Breast Carcinoma · TNBC - Triple-Negative Breast Cancer
United States
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate CancerRecruiting
NCT05803941Phase 4Updated Jun 4, 2026
Sponsor: Novartis Pharmaceuticals
Prostate Cancer
United States, Austria, Belgium, Canada, Czechia +6 more
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation DetectedTerminated
NCT04729387Phase 3Updated Jun 4, 2026
Sponsor: Novartis Pharmaceuticals
Ovarian Cancer
United States, Argentina, Australia, Austria, Belgium +21 more
A Study of 177Lu-PSMA-617 in People With GliomasRecruiting
NCT07223034Phase 1Updated Jun 4, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Glioma · Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4) · Glioblastoma, IDH-wildtype · Diffuse Midline Glioma, H3 K27-Altered
United States
A Study to Evaluate the Impact of Long-term Digital Education vs Standard of Care on LDL-C Levels in Post Myocardial Infarction PatientsCompleted
NCT06548555N/AUpdated Jun 4, 2026
Sponsor: Novartis Pharmaceuticals
Myocardial Infarction
Czechia
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCLActive Not Recruiting
NCT03960840Phase 1, Phase 2Updated Jun 4, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Diffuse Large B-cell Lymphoma · Acute Lymphoblastic Leukemia
United States, Australia, Austria, France, Germany +3 more
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)Not Yet Recruiting
NCT07443137Phase 1Updated Jun 4, 2026
Sponsor: Stanford University
Large-cell Lymphoma
Study of Efficacy and Safety of Voretigene Neparvovec in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal DystrophyCompleted
NCT04516369Phase 3Updated Jun 4, 2026
Sponsor: Novartis Pharmaceuticals
Biallelic RPE65 Mutation-associated Retinal Dystrophy
Japan
Atrasentan in Patients With IgA NephropathyActive Not Recruiting
NCT04573478Phase 3Updated Jun 4, 2026
Sponsor: Novartis Pharmaceuticals
IgA Nephropathy · Immunoglobulin A Nephropathy
United States, Argentina, Australia, Brazil, Canada +15 more
Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARLNot Yet Recruiting
NCT07625306Phase 3Updated Jun 4, 2026
Sponsor: Novartis Pharmaceuticals
Acute Coronary Syndrome (ACS)
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)Recruiting
NCT06581198Phase 2Updated Jun 3, 2026
Sponsor: Novartis Pharmaceuticals
Lupus Erythematosus, Systemic · Lupus Nephritis
United States, Australia, Austria, Brazil, Czechia +18 more
Reduce Tobacco Use in People Living With HIV in SwitzerlandRecruiting
NCT06789692NAUpdated Jun 2, 2026
Sponsor: University Hospital, Basel, Switzerland
HIV · Smoking
Switzerland
The Belgian REAL (BE.REAL) RegistryActive Not Recruiting
NCT05726838N/AUpdated Jun 2, 2026
Sponsor: Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease ParticipantsActive Not Recruiting
NCT05469360Phase 1Updated Jun 1, 2026
Sponsor: Novartis Pharmaceuticals
Alzheimer Disease · Mild Cognitive Impairment
Finland, France, Spain, Sweden
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate CancerRecruiting
NCT07145177Phase 1Updated Jun 1, 2026
Sponsor: University of California, San Francisco
Metastatic Prostate Cancer · Prostate Cancer
United States
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANRecruiting
NCT06994845Phase 3Updated Jun 1, 2026
Sponsor: Novartis Pharmaceuticals
Primary Immunoglobulin A Nephropathy (IgAN)
United States, Australia, China, Hong Kong, Israel +2 more
A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.Not Yet Recruiting
NCT07618390Phase 2Updated Jun 1, 2026
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Atrasentan in Patients With Proteinuric Glomerular DiseasesActive Not Recruiting
NCT04573920Phase 2Updated Jun 1, 2026
Sponsor: Novartis Pharmaceuticals
IgA Nephropathy · Focal Segmental Glomerulosclerosis · Alport Syndrome · Diabetic Kidney Disease
United States, Australia, Italy, South Korea, Spain +1 more
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South KoreaRecruiting
NCT05703516N/AUpdated Jun 1, 2026
Sponsor: Novartis Pharmaceuticals
Non-Small-Cell Lung Carcinoma
South Korea
A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in ChinaRecruiting
NCT06931691N/AUpdated Jun 1, 2026
Sponsor: Novartis Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria
China
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruiting
NCT02693535Phase 2Updated May 29, 2026
Sponsor: American Society of Clinical Oncology
Lymphoma, Non-Hodgkin · Multiple Myeloma · Advanced Solid Tumors
United States, Puerto Rico
Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal PolypsCompleted
NCT05626257N/AUpdated May 29, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Rhinosinusitis With Nasal Polyps
South Korea
ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)Not Yet Recruiting
NCT07448610Phase 4Updated May 29, 2026
Sponsor: Novartis Pharmaceuticals
Spinal Muscular Atrophy

Previous page Next page